Todd Carter
Equibles does not estimate personal net worth.
About Todd Carter
Voyager Therapeutics, Inc. reported in an 8-K filed September 7, 2022 that Todd Carter was appointed Chief Scientific Officer, effective September 19, 2022. Voyager Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Voyager Therapeutics, Inc. includes Alfred Sandrock (CEO and Board Member), Alfred Sandrock, M.D., Ph.D. (CEO and Board Member), Michael Higgins (CEO and Board Member) and 7 others.
“On September 7, 2022, the Company and Todd Carter, Ph.D. entered into a second amended and restated employment agreement (the “Carter Agreement”), pursuant to which Dr. Carter agreed to serve as the Chief Scientific Officer of the Company, effective on September 19, 2022 (the “Carter Promotion Date”).”
Affiliation history
-
Voyager Therapeutics, Inc. (VYGR)
Proxy statement
CurrentStart not stated–present
Last confirmed April 28, 2026
Company network
Leadership on record at Voyager Therapeutics, Inc.
- Alfred Sandrock CEO, Board Member
- Alfred Sandrock, M.D., Ph.D. CEO, Board Member
- Michael Higgins CEO, Board Member
- Nathan Jorgensen, Ph.D., M.B.A. CFO
- Peter P. Pfreundschuh CFO
- Robin Swartz CFO, COO
- Glenn Pierce, M.D., Ph.D. CTO, Board Member
- Gregory Shiferman General Counsel
- Amy Quinlan Chief Accounting Officer
- Julie Burek Chief Accounting Officer